A cannabinoid Hairy-Tale: Hair loss or hair gain?
androgenetic alopecia
cannabidiol
cannabinoids
phytocannabinoids
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
revised:
22
09
2022
received:
20
07
2022
accepted:
29
09
2022
pubmed:
2
10
2022
medline:
6
1
2023
entrez:
1
10
2022
Statut:
ppublish
Résumé
Few studies have reported on the use of cannabinoid products to treat hair loss. This article aims to reconcile cannabinoids' impact on hair growth. A comprehensive and structured search was conducted in PubMed and Google Scholar on June 23, 2022. While cannabidiol (CBD), a phytocannabinoid, may cause hair growth, several other phytocannabinoids may lead to hair loss. Additionally, the effect of CBD on hair growth may be concentration-dependent. CBD may cause hair loss at high concentrations (≥10 μM). Therefore, the concentration of CBD needs to be adjusted so that it is optimal for hair growth. One trial found that once-daily application of CBD-rich topical cannabis extract for 6 months increased nonvellus hair count by approximately 93.5% in 35 Caucasian AGA patients: 28 males aged 28-72 years [average 43 years] and 7 females aged 46-76 years [average 61 years]. Each application contained 3-4 mg of CBD. The CBD-rich topical cannabis extract was prepared by ultra-pulverizing Cannabis sativa [hemp] flower into a green chalk-like powder [10.78% CBD and 0.21% tetrahydrocannabinol] and then infusing the powder into a lanolin paste and Emu oil carrier. Topical CBD preparations require further studies to establish their safety and efficacy profile. An ideal topical cannabinoid preparation should contain CBD at the right concentration and lack other phytocannabinoid adulterants.
Sections du résumé
BACKGROUND
BACKGROUND
Few studies have reported on the use of cannabinoid products to treat hair loss.
AIM
OBJECTIVE
This article aims to reconcile cannabinoids' impact on hair growth.
METHOD
METHODS
A comprehensive and structured search was conducted in PubMed and Google Scholar on June 23, 2022.
RESULT
RESULTS
While cannabidiol (CBD), a phytocannabinoid, may cause hair growth, several other phytocannabinoids may lead to hair loss. Additionally, the effect of CBD on hair growth may be concentration-dependent. CBD may cause hair loss at high concentrations (≥10 μM). Therefore, the concentration of CBD needs to be adjusted so that it is optimal for hair growth. One trial found that once-daily application of CBD-rich topical cannabis extract for 6 months increased nonvellus hair count by approximately 93.5% in 35 Caucasian AGA patients: 28 males aged 28-72 years [average 43 years] and 7 females aged 46-76 years [average 61 years]. Each application contained 3-4 mg of CBD. The CBD-rich topical cannabis extract was prepared by ultra-pulverizing Cannabis sativa [hemp] flower into a green chalk-like powder [10.78% CBD and 0.21% tetrahydrocannabinol] and then infusing the powder into a lanolin paste and Emu oil carrier.
CONCLUSION
CONCLUSIONS
Topical CBD preparations require further studies to establish their safety and efficacy profile. An ideal topical cannabinoid preparation should contain CBD at the right concentration and lack other phytocannabinoid adulterants.
Substances chimiques
Cannabidiol
19GBJ60SN5
Cannabinoids
0
Plant Extracts
0
Powders
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
6653-6660Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Rogers NE, Avram MR. Medical treatments for male and female pattern hair loss. J Am Acad Dermatol. 2008;59(4):547-566.
Gupta AK, Talukder M. Topical finasteride for male and female pattern hair loss: is it a safe and effective alternative? J Cosmet Dermatol. 2022;21:1841-1848.
Rogers NE, Gupta AK. Medical treatments for male and female pattern hair loss. In: Unger WP, ed. Hair Transplantation. 6th ed. Informa Healthcare; in press:38-46.
Gupta AK, Talukder M, Venkataraman M, Bamimore MA. Minoxidil: a comprehensive review. J Dermatolog Treat. 2021;33(4):1896-1906.
Gupta AK, Venkataraman M, Talukder M. Bamimore M. J Dermatolog Treat; 2021:1-37.
Bíró T, Bodó E, Telek A, et al. Hair cycle control by vanilloid receptor-1 (TRPV1): evidence from TRPV1 knockout mice. J Invest Dermatol. 2006;126(8):1909-1912.
Del Río C, Millán E, García V, Appendino G, DeMesa J, Muñoz E. The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders. Biochem Pharmacol. 2018;157:122-133.
Laprairie R, Bagher A, Kelly M, Denovan-Wright E. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015;172(20):4790-4805.
Muller C, Morales P, Reggio PH. Cannabinoid ligands targeting TRP channels. Front Mol Neurosci. 2019;11:487.
Paronis CA, Nikas SP, Shukla VG, Makriyannis A. Δ9-tetrahydrocannabinol acts as a partial agonist/antagonist in mice. Behav Pharmacol. 2012;23(8):802-805.
Smith G, Satino J. Hair regrowth with cannabidiol (CBD)-rich hemp extract. Cannabis. 2021;4(1):53-59.
Szabó IL, Herczeg-Lisztes E, Szegedi A, et al. Transient receptor potential vanilloid 4 is expressed in human hair follicles and inhibits hair growth in vitro. J Investig Dermatol. 2018;139:1385-1388.
Szabó IL, Lisztes E, Béke G, et al. The phytocannabinoid (−)-cannabidiol (CBD) operates as a complex, differential modulator of human hair growth: anti-inflammatory submicromolar versus hair growth inhibitory micromolar effects. J Invest Dermatol. 2020;140(2):484-488.
Telek A, Bíró T, Bodó E, et al. Inhibition of human hair follicle growth by endo-and exocannabinoids. FASEB J. 2007;21(13):3534-3541.
Gupta AK, Talukder M. Cannabinoids for skin diseases and hair regrowth. J Cosmet Dermatol. 2021;20:2703-2711.
Sivesind TE, Maghfour J, Rietcheck H, Kamel K, Malik AS, Dellavalle RP. Cannabinoids for the treatment of dermatologic conditions. JID Innovations. 2022;2:100095.
Crawley A, LeBras M, Regier L. Cannabinoids: overview (RxFiles). 2021; www.RxFiles.ca. Accessed 18 May, 2021.
Inroduction to the skin endocannabinoid system - Phytecs. http://www.phytecs.com/tour-the-ecs/the-ecs-in-skin/. Accessed 31 May, 2021.
Bíró T, Tóth BI, Haskó G, Paus R, Pacher P. The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends Pharmacol Sci. 2009;30(8):411-420.
Turner SE, Williams CM, Iversen L, Whalley BJ. Molecular pharmacology of Phytocannabinoids. Phytocannabinoids. 2017;103:61-101.
Bunka D, LeBras M, Oroz I. Topical Cannabis: Does it Live Up to its Presumed Potential? (RxFiles). 2019; www.RxFiles.ca. Accessed 18 May, 2021.
Del Rosso JQ. Use of a palmitoylethanolamide-containing nonsteroidal cream for treating atopic dermatitis: impact on the duration of response and time between flares. Cosmetic Dermatology. 2007;20(4):4.
Eberlein B, Eicke C, Reinhardt HW, Ring J. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol Venereol. 2008;22(1):73-82.
Visse K, Blome C, Phan NQ, Augustin M, Ständer S. Efficacy of body lotion containing N-palmitoylethanolamine in subjects with chronic pruritus due to dry skin: a dermatocosmetic study. Acta Derm Venereol. 2017;97(5):639-641.
A booklet for people thinking about starting medical cannabis (RxFiles). www.RxFiles.ca. Accessed 18 May, 2021.